COPD, Smoking Increase Death Risk in COVID-19 Patients, Study Says

Smokers and people with chronic obstructive pulmonary disease (COPD) are more likely to develop severe complications and die from COVID-19 infections than infected patients who do not smoke or have COPD, a recent meta-analysis shows. This research, however, suggests that the prevalence of COPD patients and smokers among…

Early Trial Findings Hint at SNG001 Aiding COPD Patients with Viral Infections

Viral respiratory infections, like those caused by a cold or flu, may particularly aggravate symptoms of chronic obstructive pulmonary disease (COPD), according to early data from a clinical trial testing the safety and effectiveness of SNG001, an inhaled interferon-beta therapy by Synairgen. These latest preliminary findings in the…

COPD Patients Begin to Receive Synairgen’s Therapy SNG001 for Flu, Colds in Phase 2 Trial

Treatment administration has started in the second part of a Phase 2 trial evaluating the safety and efficacy of Synairgen‘s inhaled therapeutic candidate SNG001 in patients with chronic obstructive pulmonary disease (COPD) with a confirmed flu or cold virus. SNG001 is an inhaled interferon-beta (IFN-beta) therapy developed to help…